ACST Acasti Pharma, Inc.

1.31
+0  (1%)
Previous Close 1.30
Open 1.32
Price To book 0.94
Market Cap 14.03M
Shares 10,712,000
Volume 4,668
Short Ratio 1.97
Av. Daily Volume 125,589

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated 2H 2017.
CaPre (TRIFECTA trial)
Hypertriglyceridemia

Latest News

  1. Acasti Pharma to Present CaPre Omega-3 Bridging Study Results at National Lipid Association Scientific Sessions
  2. Acasti Pharma Provides Update On CaPre Phase 3 Development Program
  3. Acasti Pharma Forms Scientific Advisory Board and Appoints Two Leading Cardiovascular Disease Experts
  4. Acasti Pharma Grants Incentive Stock and Options
  5. Acasti Pharma Announces Proposed Private Placement of Convertible Debentures and Amended Proposed Offering of Units
  6. Biotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and Acasti Pharma
  7. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q3, 2017 By the Numbers : January 16, 2017
  8. Acasti reports 3Q loss
  9. Acasti Pharma Reports Third Quarter 2017 Financial Results
  10. Acasti Pharma Appoints Linda O'Keefe as Chief Financial Officer
  11. Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV
  12. Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre
  13. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q2, 2017 By the Numbers : October 14, 2016
  14. Acasti Pharma Reports Second Quarter 2017 Financial Results
  15. McDonald’s Corporation (MCD), AcelRx Pharmaceuticals Inc. (ACRX) & More: Here’s Why These Stocks Are Trending Today
  16. Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data
  17. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q1, 2017 By the Numbers : July 22, 2016
  18. Acasti Announces First Quarter Results